Name: 高危皮肤鳞状细胞癌患者的预后40基因表达谱测试真实世界证据数据集
Creator: Taylor & Francis
License: CC BY 4.0

基本信息

模态

表格

大小

0.000386131 GB

许可

CC BY 4.0

创建/更新时间

2022-11-03

版本

v2

资源简介

高危皮肤鳞状细胞癌患者的预后40基因表达谱测试真实世界证据数据集

【一句话概览】

本数据集是 figshare 公开的结构化表格数据集，收录 7 个文件、合计 386.13 KB，主题涵盖 Cutaneous squamous cell carcinoma (cSCC)、40-gene expression profile (40-GEP)、metastasis、prognostic、risk-stratification，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。

【数据集背景】

本数据集源站标题为《Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients》。配套论文《Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients》发表于 Cancer Investigation（2022），DOI：10.1080/07357907.2022.2116454。项目资助方：This work was supported by Castle Biosciences, Inc.。源站首次发布：2022-09-16。

【数据内容】

源站原始描述：Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. The 40-gene expression profile (40-GEP) test was developed to augment metastatic risk prediction of high-risk cSCC patients and has been validated in two independent, multi-ce…

中文译文（机器翻译，仅供快速理解，请以原文为准）：皮肤鳞状细胞癌（cSCC）患者的治疗决策传统上基于临床病理危险因素和分期系统。由于这些资源在预测不良结局方面的准确性有限，临床上迫切需要更准确的风险评估方法。40基因表达谱（40-GEP）检测的开发旨在增强高危cSCC患者的转移风险预测，并已在两项涉及超过1,000例患者的独立、多中心研究中得到验证。本研究证实，临床医生恰当地应用了40-GEP，并且个性化的风险分层结果对指导与风险相匹配的患者管理具有重要影响。

【数据结构与技术规格】

文件数 7 个，合计 386.13 KB。icnv_a_2116454_sm0325.docx：undefined，67.72 KB。icnv_a_2116454_sm0324.docx：undefined，64.60 KB。icnv_a_2116454_sm0323.docx：undefined，65.00 KB。数据集 DOI：10.6084/m9.figshare.21065459.v2。

【主题与分类】

源站学科分类：Medicine、Cell Biology、Genetics、Biotechnology、Immunology、Mathematical Sciences not elsewhere classified。主题标签：Cutaneous squamous cell carcinoma (cSCC)、40-gene expression profile (40-GEP)、metastasis、prognostic、risk-stratification。

【适用方向】

结构化表格数据可直接用于统计建模、特征工程与队列分析。

【获取与许可】

源站页面：https://tandf.figshare.com/articles/dataset/Real-world_Evidence_Shows_Clinicians_Appropriately_Use_the_Prognostic_40-gene_Expression_Profile_40-GEP_Test_for_High-risk_Cutaneous_Squamous_Cell_Carcinoma_cSCC_Patients/21065459

使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。

规范引用：Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. Taylor & Francis. Hooper, Perry B.; Farberg, Aaron S.; Fitzgerald, Alison L.; Siegel, Jennifer J.; Rackley, Briana B.; Prasa…

【使用注意】

· 源站最后修改于 2023-06-01，引用时请注意版本时效。

原始链接

https://tandf.figshare.com/articles/dataset/Real-world_Evidence_Shows_Clinicians_Appropriately_Use_the_Prognostic_40-gene_Expression_Profile_40-GEP_Test_for_High-risk_Cutaneous_Squamous_Cell_Carcinoma_cSCC_Patients/21065459/2

访问原始数据

官方服务

专家保障全链路合规授权与标注交付

陕川双基地 × 超十家三甲医院直连

从合规授权、采集治理、专业标注到数据集交付，我们提供全链路闭环服务，让高质量临床数据即拿即用。

⚡️ 需要原始数据或标注支持？联系我们获取定制方案。

帮我联系

下载信息

注册下载

需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。

暂未开放

公开下载

无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。

免登录

有偿下载

公开数据集受托下载与技术交付服务。

提供高速下载与技术交付服务（收技术服务费，非数据销售）

暂未开放

当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。

使用方式

数据集获取（Figshare）

源站标题：Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
DOI：10.6084/m9.figshare.21065459.v2
发布日期：2022-09-16
文件数：7 个
文件总体积：386.13 KB
源站页面：https://tandf.figshare.com/articles/dataset/Real-world_Evidence_Shows_Clinicians_Appropriately_Use_the_Prognostic_40-gene_Expression_Profile_40-GEP_Test_for_High-risk_Cutaneous_Squamous_Cell_Carcinoma_cSCC_Patients/21065459

命令行下载

curl -L -o "icnv_a_2116454_sm0325.docx" "https://ndownloader.figshare.com/files/37478998"
curl -L -o "icnv_a_2116454_sm0324.docx" "https://ndownloader.figshare.com/files/37479001"
curl -L -o "icnv_a_2116454_sm0323.docx" "https://ndownloader.figshare.com/files/37479004"
curl -L -o "icnv_a_2116454_sm0322.docx" "https://ndownloader.figshare.com/files/37479007"
curl -L -o "icnv_a_2116454_sm0321.docx" "https://ndownloader.figshare.com/files/37479010"
curl -L -o "icnv_a_2116454_sm0320.docx" "https://ndownloader.figshare.com/files/37479013"
curl -L -o "icnv_a_2116454_sm0319.docx" "https://ndownloader.figshare.com/files/37479016"

文件清单

icnv_a_2116454_sm0325.docx（67.72 KB）
icnv_a_2116454_sm0324.docx（64.60 KB）
icnv_a_2116454_sm0323.docx（65.00 KB）
icnv_a_2116454_sm0322.docx（65.50 KB）
icnv_a_2116454_sm0321.docx（65.03 KB）
icnv_a_2116454_sm0320.docx（44.05 KB）
icnv_a_2116454_sm0319.docx（14.23 KB）

文件总体积 386.13 KB（源站 API 实测）。

数据说明

Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. The 40-gene expression profile (40-GEP) test was developed to augment metastatic risk prediction of high-risk cSCC patients and has been validated in two independent, multi-center studies involving over 1,000 patients. This study substantiates that the 40-GEP is appropriately utilized by clinicians and that the personalized risk-stratification results are impactful in guiding risk-aligned patient management.